SS-31, also known as elamipretide, is a synthetic mitochondria-targeting tetrapeptide in the Szeto-Schiller family that concentrates on the inner mitochondrial membrane and binds cardiolipin to help preserve energy production. In September 2025 it received FDA accelerated approval as FORZINITY for Barth syndrome, making it the first approved mitochondria-targeted drug, while remaining investigational for every other use. The gap between an interesting mechanism and proven clinical benefit is the central fact for anyone evaluating it.
In September 2025 elamipretide became the first FDA-approved mitochondria-targeted drug, cleared under accelerated approval as FORZINITY for Barth syndrome, while remaining investigational for all other indications.
The chemistry explains the behavior. SS-31 carries a positive charge that pulls it toward the negatively charged interior of energized mitochondria, and it is lipophilic enough to cross membranes without a transporter. Once concentrated on the inner mitochondrial membrane it binds cardiolipin, the phospholipid that holds cristae folded and keeps the electron transport chain organized.
SS-31 is a Szeto-Schiller tetrapeptide that concentrates several thousand-fold on the inner mitochondrial membrane and binds cardiolipin, aiming to preserve cristae structure and reduce reactive-oxygen-species production rather than scavenge free radicals after they form.
The list of target conditions follows straight from the mechanism: the tissues that burn the most energy are the ones most vulnerable when mitochondria fail. Heart, skeletal muscle, retina, kidney, and brain have all drawn research interest, though being studied in a condition is not the same as being proven effective for it.
SS-31 has been investigated across primary mitochondrial myopathy, heart failure, ischemia-reperfusion injury, dry age-related macular degeneration, Barth syndrome, and certain kidney conditions, yet several of these late-stage programs produced disappointing or mixed results.
The honest summary is a split record: a strong preclinical file and an inconsistent clinical one. Animal models and early mechanistic human work repeatedly improved measures of mitochondrial function, which justified moving into larger trials. Those larger trials are where the story became complicated.
| Evidence stage | What the record reports | Strength |
|---|---|---|
| Preclinical and early human | Repeated improvement in mitochondrial function and muscle energetics | Encouraging but early |
| Pivotal myopathy trial | Missed its primary six-minute-walk endpoint, with scattered secondary signals | Unproven |
| Cardiology trials | Heart failure and ischemia-reperfusion studies missed primary outcomes | Negative |
| Barth syndrome approval | 2025 accelerated approval on an intermediate strength endpoint | Clinical benefit unconfirmed |
SS-31 has a strong preclinical record but an inconsistent clinical one, its pivotal mitochondrial myopathy trial missed the six-minute-walk primary endpoint, cardiology trials failed their primary outcomes, and even its 2025 Barth syndrome approval rests on an intermediate marker awaiting confirmatory trial data.
Within its clinical trials, elamipretide was generally described as reasonably well tolerated, one of the more favorable parts of its record. That reassurance came from pharmaceutical-grade material dosed and monitored in a supervised setting, and it does not transfer to a vial bought online.
In clinical trials elamipretide was generally well tolerated, with mostly mild injection-site reactions, headache, gastrointestinal upset, and dizziness, but that tolerability reflects pharmaceutical-grade material under medical supervision and does not extend to research-labeled product bought online.
One narrow approval does not legalize the rest. As FORZINITY, elamipretide gained FDA accelerated approval for Barth syndrome in September 2025, dispensed through a specialty pharmacy, while for every other use it stays investigational and has no comparable EMA approval. The "research use only" label on online product is not a mark of quality but a way to sell a substance outside the drug-approval and prescribing system.
| Feature | FDA-approved prescription (FORZINITY) | Research-labeled SS-31 online |
|---|---|---|
| Evidence file | Regulator-reviewed | None |
| Manufacturing | Enforced pharmaceutical standard | No assured standard |
| Labeling | Official indications and warnings | "Research use only" |
| Oversight | Prescriber accountable | No clinician between buyer and vial |
Elamipretide holds a single FDA accelerated approval, as FORZINITY for Barth syndrome dispensed by specialty pharmacy since September 2025, while SS-31 sold online as "research use only" is marketed outside the drug-approval system and carries no assurance of identity, purity, or legal standing as a medicine.
In clinical research, elamipretide was given by injection, with the route and schedule set by each trial's design. The specific doses were selected, escalated, and monitored by investigators using pharmacokinetic data and safety oversight that an individual does not have, which is why published trial numbers do not function as a home recipe.
In trials elamipretide was dosed by daily subcutaneous injection in mitochondrial myopathy and by intravenous infusion in some cardiac studies under investigator monitoring, and no validated dosing protocol exists for SS-31 outside a clinical trial.
In the research-peptide market, SS-31 is generally sold as a lyophilized powder priced from roughly tens of dollars to over a hundred dollars per vial, depending on labeled quantity, vendor, and purity claims. A low price is a poor signal of value, since in an unregulated market an unusually cheap vial more often points to underfilled or impure product than to a bargain.
Research-labeled SS-31 sells for roughly tens to over a hundred dollars per vial with no assurance of its contents, while the only quality-controlled elamipretide reaches people as prescription FORZINITY for Barth syndrome or as trial-supplied drug under medical supervision.
SS-31 sits at the experimental, targeted end of a spectrum of approaches to mitochondrial support. Familiar oral options such as coenzyme Q10, creatine, and B-vitamin cofactors work broadly and indirectly, and general antioxidants neutralize free radicals after they form. SS-31's distinctive feature is that it acts on cardiolipin specifically, a more precise strategy that does not translate into a stronger evidence base.
| Approach | How it works | Evidence base |
|---|---|---|
| CoQ10, creatine, cofactors | Broad, indirect substrate support, taken orally | Decades of use, some defined roles |
| General antioxidants | Neutralize free radicals after they form | Broad and non-specific |
| SS-31 (elamipretide) | Targets cardiolipin to cut free-radical generation | Investigational, one narrow approval |
| Aerobic and resistance exercise | Raises mitochondrial density and function | Best-validated, broad benefit |
SS-31 is a more targeted mitochondrial agent than broad supplements such as coenzyme Q10 or general antioxidants, but it remains investigational for nearly all uses with a single narrow approval, while regular aerobic and resistance exercise is the best-validated way to raise mitochondrial capacity in most people.
The most useful starting point separates the appeal of the mechanism from the state of the proof. Outside its narrow Barth syndrome approval, SS-31 is an investigational drug whose larger human trials have largely failed to confirm clear benefit, so use for other purposes runs well ahead of the evidence.
For any use beyond its narrow Barth syndrome approval, SS-31 remains an investigational compound with unconfirmed efficacy and an unregulated supply, which is why the published record points toward established options and qualified clinical guidance before an unapproved peptide.
Educational use only. This article describes what the published scientific and clinical literature reports about SS-31. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
